Jhunjhunwala-backed Concord Biotech sets IPO price band at Rs 705-741
According to the draft papers, Concord Biotech’s IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investment Holdings Pte Limited, backed by private equity firm Quadria Capital.
